Haiming M Chen

US Patent:

7566456, Jul 28, 2009

Filed:

Jun 23, 2006

Appl. No.:

11/474180

Inventors:

Haiming Chen - West Hills CA, US

International Classification:

C07K 14/00
C07K 17/00
A61K 39/00
A61K 39/35
A61K 39/36

US Classification:

4241851, 4241921, 4242751, 530350

Abstract:

The present invention provides fusion proteins comprising an allergen sequence linked via an IgG hinge region to another polypeptide sequence capable of specifically binding to a native IgG inhibitory receptor containing an immune receptor tyrosine based inhibitory motif (ITIM). They are designed to cross-link an Fc receptor for IgE (e. g. , FcεR1) and an IgG inhibitory receptor (e. g. , FcγRIIb), thereby inhibiting the IgE-driven mediators released from mast cells and basophils. In addition, the present invention provides nucleic acid molecules encoding the fusion proteins, vectors and host cells for producing the fusion proteins, pharmaceutical compositions comprising the fusion proteins, and methods for ameliorating or reducing the risk of IgE-medicated allergic diseases.

US Patent:

20080015347, Jan 17, 2008

Filed:

May 8, 2004

Appl. No.:

10/592376

Inventors:

Haiming Chen - Los Angeles CA, US
Junyu Gao - Beijing, CN

International Classification:

A61K 38/00
A61P 43/00
C07K 14/00
C12N 15/00
C12N 15/11
C12N 5/06
C12P 21/04

US Classification:

536 234, 4353201, 435325, 435 691, 514 12, 530350

Abstract:

This invention provides a fusion protein (FP4) and the code gene, expression method, and clinical application; its goal is to provide a fusion protein, the code gene, and the expression method as well as to take this fusion protein as the active constituent anti-allergic medicine. In addition, the invention provides the sequence of fusion protein attached on SEQ ID 2 and any derivation protein of the fusion protein (FP4) which includes adding or deleting several amino acids of SEQ ID2 as well as increasing or deducing nuclear tides of SEQ ID 1. We designed to cross-link IgE active receptor and an IgG inhibitory receptor by endogens hinge without any extraneous chemical link. This invention fusion protein has function to block the IgE acceptor, moreover fragment of fusion protein has ability to specifically bind to a native IgG inhibitory receptor containing immunoreceptor tyrosine-based inhibitory motif, thereby inhibiting the IgE-driven mediator release from mast cells and basophils. It will play important role in the allergic disease treatment.

US Patent:

20160131654, May 12, 2016

Filed:

Feb 7, 2014

Appl. No.:

14/766694

Inventors:

- West Hollywood, CA, US
Haiming CHEN - West Hollywood CA, US
Eric SANCHEZ - West Hollywood CA, US

International Classification:

G01N 33/574

Abstract:

The invention generally provides improved compositions and methods for detecting, diagnosing, prognosing, and monitoring multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in a subject. In particular, the invention provides methods for detecting BCMA in subjects to reliably diagnose, predict survival, or monitor multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in the subject.